162 related articles for article (PubMed ID: 37795408)
21. Association Between Serum Total IgE Levels and Clinical Response to Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.
Chuang KW; Hsu CY; Huang SW; Chang HC
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2382-2389.e3. PubMed ID: 37263348
[TBL] [Abstract][Full Text] [Related]
22. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
23. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
[TBL] [Abstract][Full Text] [Related]
24. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2022 Jan; 54(1):30-33. PubMed ID: 33555151
[No Abstract] [Full Text] [Related]
25. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
[No Abstract] [Full Text] [Related]
26. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
Cakmak ME; Yeğit OO; Öztop N
Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
[TBL] [Abstract][Full Text] [Related]
27. Clinical and laboratory parameters associated with treatment response to third-line therapies in chronic refractory urticaria: A real world study from northern India.
Mehta H; Bishnoi A; Parsad D; Kumaran MS
Dermatol Ther; 2022 Nov; 35(11):e15887. PubMed ID: 36181400
[TBL] [Abstract][Full Text] [Related]
28. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria.
Acer E; Kaya Erdogan H; Yüksel Çanakçı N; Saracoglu ZN
Cutan Ocul Toxicol; 2019 Mar; 38(1):5-8. PubMed ID: 29969297
[TBL] [Abstract][Full Text] [Related]
29. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
30. IFN-γ/IL-6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy.
Grieco T; Porzia A; Paolino G; Chello C; Sernicola A; Faina V; Carnicelli G; Moliterni E; Mainiero F
Int J Dermatol; 2020 May; 59(5):590-594. PubMed ID: 32048727
[TBL] [Abstract][Full Text] [Related]
31. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
32. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
[No Abstract] [Full Text] [Related]
33. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
Cakmak ME
Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
[TBL] [Abstract][Full Text] [Related]
34. Unveiling chronic spontaneous urticaria pathophysiology through systems biology.
Segú-Vergés C; Gómez J; Terradas-Montana P; Artigas L; Smeets S; Ferrer M; Savic S
J Allergy Clin Immunol; 2023 Apr; 151(4):1005-1014. PubMed ID: 36587849
[TBL] [Abstract][Full Text] [Related]
35. Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
Asero R; Ferrucci SM; Calzari P; Consonni D; Cugno M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108654
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of omalizumab on peripheral blood cells and C-reactive protein levels in patients with chronic spontaneous urticaria.
Akdogan N; Demirel Ogut N; Dogan S; Atakan N
Dermatol Ther; 2019 Jul; 32(4):e12966. PubMed ID: 31087491
[TBL] [Abstract][Full Text] [Related]
37. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
[TBL] [Abstract][Full Text] [Related]
38. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
39. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
Front Immunol; 2021; 12():635069. PubMed ID: 33737936
[TBL] [Abstract][Full Text] [Related]
40. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.
Can PK; Etikan P; Degirmentepe EN; Kocaturk E
Asian Pac J Allergy Immunol; 2024 Jun; 42(2):132-137. PubMed ID: 33638627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
